Lilly Cal Bio nasal insulin
Executive Summary
California Biotech's letter of intent agreement with Lilly covering the development of intranasal insulin has been extended from June 1 to Sept. 5 in order to allow the biotech firm to complete Phase I studies of the intranasal insulin product.